Last updated on December 2017

A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06687234 as Add-On Therapy to Infliximab in Active Ulcerative Colitis Subjects Who Are Not in Remission


Brief description of study

This is a phase 2a, randomized, double-blind, placebo-controlled, parallel group, multicenter study in subjects with active UC and a non-remission response to infliximab.

 

There will be up to 13 study visits, across the 12 weeks of treatment, along with 2 follow-up visits, at Weeks 16 and 22.

Ideal patients for this study will have a flexible schedule, as they will be required to come in for weekly study visits.

Clinical Study Identifier: TX155002

Find a site near you

Start Over

Gastroenterology Associates of Tidewater

112 Gainsborough Square; Suite 200 Chesapeake, VA USA
  Connect »